– CANADA, Montreal – Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the appointment of industry veteran, Pierre Legault, MBA, CA, CPA to the company’s board of directors.
Mr. Legault is an accomplished leader in the biopharmaceutical industry with a proven track record, serving as chief executive officer or chief financial officer, leading corporate and business development and creating significant value for a premier set of international biopharmaceutical companies. In addition, Mr. Legault has significant experience as a director, serving on the board of many private and public companies.
“We are very pleased to welcome Pierre to Clementia’s board of directors, where his broad experience in global finance, operations, business development and commercialization will be a valuable asset as we advance palovarotene in pivotal trials for fibrodysplasia ossificans progressiva and multiple osteochondromas and towards potential commercialization,” said David Bonita, MD, chairman of the board of Clementia.
Mr. Legault is currently the chairman of Poxel and serves on the board of directors for Syndax Pharmaceuticals and ARMO BioSciences. Previously, Mr. Legault served on the board of Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Regado Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and Nephrogenex where he was chairman and CEO.
Prior to that, Mr. Legault served as the CEO of Prosidion Ltd, CFO and treasurer of OSI Pharmaceuticals, president of Eckerd Pharmacies and senior executive vice president and chief administration officer of the Rite Aid Corporation. He was also president, CEO and CFO at legacy companies of the Sanofi group.
Mr. Legault holds an MBA in marketing from McGill University and a bachelor’s degree from HEC (University of Montreal) and also studied at Harvard Business School.
“I am excited to join Clementia at this important juncture, following the completion of a very successful initial public offering last summer and the recent initiation of a registration trial for palovarotene in FOP,” said Mr. Legault. “I believe that Clementia is well positioned for success, and I look forward to working with management and the board to ultimately bring palovarotene to patients.”
About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases.
For more information : http://www.clementiapharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.